<code id='ED8B402199'></code><style id='ED8B402199'></style>
    • <acronym id='ED8B402199'></acronym>
      <center id='ED8B402199'><center id='ED8B402199'><tfoot id='ED8B402199'></tfoot></center><abbr id='ED8B402199'><dir id='ED8B402199'><tfoot id='ED8B402199'></tfoot><noframes id='ED8B402199'>

    • <optgroup id='ED8B402199'><strike id='ED8B402199'><sup id='ED8B402199'></sup></strike><code id='ED8B402199'></code></optgroup>
        1. <b id='ED8B402199'><label id='ED8B402199'><select id='ED8B402199'><dt id='ED8B402199'><span id='ED8B402199'></span></dt></select></label></b><u id='ED8B402199'></u>
          <i id='ED8B402199'><strike id='ED8B402199'><tt id='ED8B402199'><pre id='ED8B402199'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:56681
          a liver made up by geometric shapes – biotech coverage from STAT
          Adobe

          LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

          The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%. 

          advertisement

          In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Tori Bowie and the unacceptable rates of Black maternal death
          Tori Bowie and the unacceptable rates of Black maternal death

          AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

          read more
          New Covid vaccine is recommended for everyone 6 months or older
          New Covid vaccine is recommended for everyone 6 months or older

          AnurseloadsasyringewithaModernaCovidboosterataninoculationstationnexttoJacksonStateUniversityinJacks

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Acelyrin, a rare IPO success, stumbles in its first big test

          MarkLennihan/APThebiotechcompanyAcelyrin,whichraisedmorethan$500millioninanIPOthisyear,ranintoitsfir